Filana Therapeutics, Inc. (FLNA)
0.8464
-0.01
(-1.27%)
USD |
NASDAQ |
Sep 02, 13:18
Filana Therapeutics Research and Development Expense (TTM) : 15.66M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.66M |
| March 31, 2026 | 17.47M |
| December 31, 2025 | 26.59M |
| September 30, 2025 | 43.27M |
| June 30, 2025 | 56.99M |
| March 31, 2025 | 67.07M |
| December 31, 2024 | 69.64M |
| September 30, 2024 | 67.84M |
| June 30, 2024 | 73.76M |
| March 31, 2024 | 83.54M |
| December 31, 2023 | 89.42M |
| September 30, 2023 | 88.34M |
| June 30, 2023 | 83.67M |
| March 31, 2023 | 76.05M |
| December 31, 2022 | 68.93M |
| September 30, 2022 | 62.07M |
| June 30, 2022 | 53.17M |
| March 31, 2022 | 40.61M |
| December 31, 2021 | 28.71M |
| September 30, 2021 | 20.26M |
| June 30, 2021 | 11.61M |
| March 31, 2021 | 8.51M |
| December 31, 2020 | 7.291M |
| September 30, 2020 | 6.64M |
| June 30, 2020 | 6.752M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.81M |
| December 31, 2019 | 5.498M |
| September 30, 2019 | 3.808M |
| June 30, 2019 | 2.758M |
| March 31, 2019 | 2.475M |
| December 31, 2018 | 2.969M |
| September 30, 2018 | 4.511M |
| June 30, 2018 | 5.694M |
| March 31, 2018 | 7.294M |
| December 31, 2017 | 7.614M |
| September 30, 2017 | 7.405M |
| June 30, 2017 | 8.443M |
| March 31, 2017 | 6.969M |
| December 31, 2016 | 9.176M |
| September 30, 2016 | 11.46M |
| June 30, 2016 | 11.16M |
| March 31, 2016 | 11.56M |
| December 31, 2015 | 9.10M |
| September 30, 2015 | 6.588M |
| June 30, 2015 | 6.348M |
| March 31, 2015 | 6.297M |
| December 31, 2014 | 7.306M |
| September 30, 2014 | 7.349M |
| June 30, 2014 | 6.677M |
| March 31, 2014 | 5.881M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| CorMedix, Inc. | 27.59M |
| Eloxx Pharmaceuticals, Inc. | 6.647M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 0.0082M |
| BioStem Technologies, Inc. | 5.309M |